No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
COR240816C230000
- 2.88
- -0.22-7.10%
15min DelayClose Jul 19 16:00 ET
3.20High2.88Low
3.20Open3.10Pre Close58 Volume764 Open Interest230.00Strike Price17.70KTurnover21.81%IV4.15%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry2.88Extrinsic Value100Contract SizeAmericanOptions Type0.3469Delta0.0285Gamma76.44Leverage Ratio-0.1040Theta0.0529Rho26.52Eff Leverage0.2196Vega
Intraday
- 5D
- Daily
News
Barclays Maintains Cencora(COR.US) With Buy Rating, Maintains Target Price $263
Barclays analyst Stephanie Davis maintains $Cencora(COR.US)$ with a buy rating, and maintains the target price at $263.According to TipRanks data, the analyst has a success rate of 42.1% and a total
Barclays Sticks to Its Buy Rating for Cencora (COR)
Cencora (NYSE:COR) Ticks All The Boxes When It Comes To Earnings Growth
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit.
Citi Maintains Cencora(COR.US) With Buy Rating, Maintains Target Price $280
Citi analyst Daniel Grosslight maintains $Cencora(COR.US)$ with a buy rating, and maintains the target price at $280.According to TipRanks data, the analyst has a success rate of 50.4% and a total
Insider Sale: Steven Collis Sells 10,755 Shares of Cencora Inc (COR)
McKesson, Cardinal, Cencora Interested in Buying Private Cancer Clinics - Report
Comments
Cencora, Inc.'s share price gain is justified by its profitability transition. The company's future financial position is crucial for shareholders. The share price momentum remains strong, indicating positive sentiment. However, investors should be aware of 2 warning signs.
Investing in Cencora (NYSE:COR) Five Years Ago Would Have Delivered You a 217% GainInvestor optimism sustains Cencora's high P/E ratio despite market forecasts, indicating potential risk if the P/E declines to reflect growth outlook. This situation could risk shareholders' investments and lead potential investors to overpay. It's suggested the current valuation may not fully justify expected growth rates.
Recent sales of Cencora shares by insiders and lack of purchases raises concerns, despite company profitability and high insider ownership. Share sales history calls for investor caution.
The company's profitability and significant share price increase over 5 years have created positive investor sentiment. Given the recent improvement in TSR, those with an optimistic perspective may view this as the company improving over time.
Read more